13.3 Colorectal Cancer & Osteoporosis Screening
Key Takeaways
- Average-risk colorectal cancer screening begins at age 45, with colonoscopy every 10 years or annual fecal immunochemical testing among the accepted options.
- Any positive non-colonoscopy screening test must be followed by diagnostic colonoscopy, not by repeating the stool test.
- WHO criteria define osteopenia as a T-score between minus 1.0 and minus 2.5 and osteoporosis as minus 2.5 or lower.
- DEXA screening is recommended for all women at 65 and older, and for younger postmenopausal women with fracture risk factors identified by a tool such as FRAX.
- Weight-bearing and resistance exercise plus adequate calcium and vitamin D form the non-pharmacologic foundation of prevention.
Colorectal Cancer (CRC) Screening Guidelines
Colorectal adenocarcinoma arises predominantly from pre-existing adenomatous polyps (adenoma-to-carcinoma sequence) over a 10- to 15-year developmental window, providing an ideal target for preventive polypectomy and early detection.
USPSTF Screening Schedule
- Routine Screening for Ages 45 to 75 Years: The USPSTF recommends routine colorectal cancer screening for all average-risk adults beginning at age 45 years and continuing through age 75 years (Grade A for ages 50-75, Grade B for ages 45-49).
- Selective Screening for Ages 76 to 85 Years: Screening should be individualized based on the patient's overall health, prior screening history, and life expectancy (Grade C recommendation). Routine screening is not recommended after age 85.
Recommended Screening Modalities & Intervals
| Screening Modality | Testing Interval | Advantages & Procedural Realities | Follow-Up Requirement |
|---|---|---|---|
| Colonoscopy | Every 10 Years | Direct full mucosal visualization from rectum to cecum; diagnostic and therapeutic (allows immediate polypectomy); gold standard. Requires bowel prep and conscious sedation. | Surveillance interval shortened to 3-5 years if high-risk adenomas or multiple polyps are detected. |
| Fecal Immunochemical Test (FIT) | Annually | High sensitivity for human hemoglobin in lower GI tract; non-invasive; low cost; no dietary or medication restrictions (unlike guaiac tests). | ANY positive FIT mandates prompt diagnostic colonoscopy. |
| Stool DNA-FIT (sDNA-FIT / Cologuard) | Every 3 Years | Combines FIT hemoglobin detection with molecular assays for abnormal methylated DNA biomarkers shed by neoplasms. Higher sensitivity for adenomas than FIT alone, but higher false-positive rate. | ANY positive sDNA-FIT mandates prompt diagnostic colonoscopy. |
| Flexible Sigmoidoscopy | Every 5 Years (or q10y if combined with annual FIT) | Visualizes distal colon and rectum (splenic flexure); limited bowel prep; no sedation required. Misses proximal colon lesions (40-50% of neoplasms). | Any polyp detected mandates full colonoscopy. |
| CT Colonography (Virtual Colonoscopy) | Every 5 Years | Non-invasive helical CT imaging of air-insufflated colon. Detects polyps ≥6 mm. Requires full bowel prep. | Extracolonic incidental findings common; any lesion ≥6 mm mandates colonoscopy. |
[!CRITICAL] AMCB Board Rule on Stool Testing: Non-invasive stool-based tests (FIT or sDNA-FIT) are purely screening tools. If a stool test returns positive, it is NEVER appropriate to repeat the stool test. A positive test indicates occult blood or neoplastic DNA; repeating the test delays diagnosis and introduces sampling error. The patient must be referred directly for a diagnostic colonoscopy.
Osteoporosis Screening & Bone Mineral Density Assessment
Osteoporosis is a systemic skeletal disorder characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, leading to bone fragility and susceptibility to low-trauma "fragility fractures" (vertebral compression fractures, femoral neck/hip fractures, and distal radius/Colles fractures). The postmenopausal decline in circulating estradiol accelerates osteoclast-mediated bone resorption relative to osteoblast bone formation.
Dual-Energy X-Ray Absorptiometry (DEXA) Indications
- Universal Screening at Age 65: The USPSTF and the National Osteoporosis Foundation recommend routine DEXA screening for all women aged 65 years and older, regardless of clinical risk factors.
- Selective Screening in Younger Postmenopausal Women (<65 Years): Screening is recommended for postmenopausal women younger than 65 if their formal clinical fracture risk assessment demonstrates a risk equal to or greater than that of a 65-year-old white woman with no additional risk factors. This is quantified as a FRAX 10-year probability of a major osteoporotic fracture ≥8.4% (or a 10-year probability of hip fracture ≥3.0%).
- Clinical Risk Factors Triggering Early Screening: Low body weight (<127 lbs / 57.6 kg or BMI <21 kg/m²), prior adult fragility fracture, parental history of hip fracture, current cigarette smoking, excessive alcohol consumption (≥3 drinks daily), chronic systemic corticosteroid therapy (≥5 mg prednisone equivalent daily for ≥3 months), rheumatoid arthritis, premature ovarian insufficiency (<40 years), or secondary causes (hyperthyroidism, celiac disease, malabsorption).
T-Score Diagnostic Criteria (WHO Standard)
The T-score compares the patient's measured BMD to the mean BMD of a healthy, young adult female reference population, expressed in standard deviations (SD):
| Diagnostic Category | T-Score Criteria (Lumbar Spine, Femoral Neck, or Total Hip) | Clinical Interpretation & Midwifery Management |
|---|---|---|
| Normal Bone Mass | T-score ≥ -1.0 SD | Routine preventive counseling: calcium 1,200 mg/day, vitamin D 800–1,000 IU/day, regular weight-bearing exercise. Repeat DEXA in 5 to 15 years. |
| Osteopenia (Low Bone Mass) | T-score between -1.0 and -2.5 SD | Calculate 10-year fracture risk via FRAX. If 10-year major osteoporotic fracture risk is ≥20% OR hip fracture risk is ≥3.0%, initiate pharmacotherapy. Repeat DEXA in 2 to 5 years. |
| Osteoporosis | T-score ≤ -2.5 SD | Formal diagnostic threshold. Warrants evaluation for secondary causes (calcium, phosphorus, 25-OH-D, TSH, creatinine) and initiation of pharmacotherapy (oral bisphosphonates). |
| Severe / Established Osteoporosis | T-score ≤ -2.5 SD PLUS history of ≥1 fragility fracture | High imminent fracture risk. Anabolic therapy or potent antiresorptive pharmacotherapy indicated. |
Note on Z-Scores: The Z-score compares BMD to age-, sex-, and ethnicity-matched peers. A Z-score ≤ -2.0 SD in a premenopausal woman is defined as "below the expected range for age" and mandates investigation for secondary causes (endocrinopathies, malabsorption, celiac disease, multiple myeloma).
Midwifery Management & Prevention of Bone Loss
- Elemental Calcium: 1,200 mg daily for all women aged 51 and older (dietary sources preferred). If supplements are required: calcium carbonate (40% elemental calcium, requires gastric acid; take with meals) or calcium citrate (21% elemental calcium, acid-independent; preferred in patients taking PPIs, H2 blockers, or with achlorhydria).
- Vitamin D3 (Cholecalciferol): 800 to 1,000 IU daily (target serum 25-hydroxyvitamin D level ≥30 ng/mL).
- Lifestyle Interventions: Regular weight-bearing exercise (walking, jogging, tennis) and progressive resistance strength training; complete smoking cessation; limiting alcohol intake to <2 drinks per day; comprehensive home fall-prevention evaluation.
- Pharmacologic Therapy: Indicated for women with a T-score ≤ -2.5, those with a hip or vertebral fragility fracture regardless of T-score, or those with osteopenia and FRAX scores exceeding the treatment threshold (≥20% major fracture or ≥3% hip fracture). First-line therapy: Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly). Patient Instructions: Take immediately upon awakening with 8 oz of plain water, on an empty stomach; remain completely upright for at least 30 to 60 minutes before ingesting any food, beverage, or other medications to prevent esophageal ulceration.
A 52-year-old postmenopausal woman presents for an annual well-woman visit. She has no chronic medical conditions, takes no medications, and has never smoked. Her family history is negative for colorectal, breast, or ovarian cancers. Her body weight is 145 lbs (BMI 24.2 kg/m²). She asks the certified nurse-midwife which routine preventive screening tests she is currently due to receive. Based on current US Preventive Services Task Force (USPSTF) guidelines, which combination of routine screening recommendations is appropriate for this patient?